ResearcherSichuan UniversityActive in the last 2 years

Ying Cao Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9057-227X; OpenAlex author ID A5014565538. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.7717/peerj.18018 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qunli Xiong · 1 shared paper, 2024 · strength 0.26
- Paper Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. DOI 10.7717/peerj.18018 ↗
Zhiwei Zhang · 1 shared paper, 2024 · strength 0.26
- Paper Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. DOI 10.7717/peerj.18018 ↗
Yongfeng Xu · 1 shared paper, 2024 · strength 0.26
- Paper Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. DOI 10.7717/peerj.18018 ↗
Qing Zhu · 1 shared paper, 2024 · strength 0.26
- Paper Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. DOI 10.7717/peerj.18018 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.